Video Experimental Relacionado
Updated: Jul 18, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
La lipoproteína es un factor de riesgo independiente para la enfermedad cardiovascular en pacientes en hemodiálisis
M D Cressman1, R J Heyka, E P Paganini
1Department of Heart and Hypertension Research, Cleveland Clinic Foundation, OH 44195-5069.
Circulation
|August 1, 1992
Resumen
El aumento de la lipoproteína [Lp] es un factor de riesgo independiente para eventos cardiovasculares ateroscleróticos en pacientes en hemodiálisis. Este estudio confirma a Lp como un predictor significativo de eventos clínicos en esta población de alto riesgo.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Nefrología Nefrología.
- Química clínica es la química clínica.
Sus antecedentes:
- La lipoproteína sérica (Lp) es un factor de riesgo conocido de aterosclerosis.
- Los niveles de Lp (a) son elevados en pacientes en hemodiálisis.
- Anteriormente no se había establecido la asociación entre Lp(a) y los eventos clínicos en pacientes en hemodiálisis.
Objetivo del estudio:
- Determinar la asociación entre los niveles de Lp (a) y el riesgo de eventos clínicos atribuidos a la aterosclerosis.
- Investigar la Lp (a) como un factor de riesgo independiente en pacientes con hemodiálisis crónica.
Principales métodos:
- Estudio prospectivo de 129 pacientes ambulatorios con hemodiálisis.
- Medición por radioinmunoensayo de los niveles basales de Lp (a).
- Seguimiento de 48 meses para evaluar los eventos clínicos de presunta etiología aterosclerótica.
Principales resultados:
- Los pacientes en hemodiálisis tenían significativamente más altos niveles medianos de Lp (a) en comparación con los controles.
- La concentración basal de Lp (a) fue un predictor significativo de eventos clínicos durante el seguimiento.
- Lp (a) y eventos clínicos previos fueron los únicos factores independientes que contribuyeron al riesgo futuro.
Conclusiones:
- El Lp de suero (a) es un factor de riesgo independiente para eventos de enfermedad cardiovascular aterosclerótica.
- Este hallazgo es significativo para los pacientes sometidos a hemodiálisis crónica por enfermedad renal terminal.
Videos de Conceptos Relacionados
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:24Hemodialysis II: Procedure and Complications
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...